Abstract
Almotriptan is a serotonin (5-hydroxytryptamine, 5-HT)1B/1D-receptor agonist approved for the acute treatment of migraine. In 3500 acute migraine patients enrolled in short-term trials and 1500 patients in long-term open-label trials, almotriptan 12.5 mg was effective and well-tolerated. Almotriptan maintains a consistency of response across three attacks and patients continue to respond to almotriptan for up to 1 year. Results from two comparative studies and a meta-analysis of 53 randomised, placebo-controlled studies of oral triptans in > 24,000 patients, confirm that almotriptan 12.5 mg demonstrates comparable efficacy with sumatriptan 50 and 100 mg. The incidence of treatment-related adverse events with almotriptan is comparable to that of placebo and significantly lower than that with sumatriptan. Drug-drug interaction studies indicate that almotriptan may be coadministered with other commonly prescribed drugs without dose modification. Almotriptan can be recommended as first-line treatment for acute migraine.
Original language | English (US) |
---|---|
Pages (from-to) | 1157-1163 |
Number of pages | 7 |
Journal | Expert Opinion on Pharmacotherapy |
Volume | 4 |
Issue number | 7 |
DOIs | |
State | Published - Jul 1 2003 |
Keywords
- Adverse events
- Almotriptan
- Efficacy
- Migraine
- Triptans
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)